Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering RNA-based medicines to restore protein expression, today reported financial results for the third quarter ended September 30, 2025, and…
Catalent Highlights Advances in SMARTag® ADC Technology and Introduces New Enhanced Conjugates at 16th World ADC San Diego TAMPA, Fla.—(BUSINESS WIRE)— Catalent, Inc., a leading global contract development and manufacturing organization, unveiled significant innovations from its SMARTag® antibody-drug conjugate (ADC)…
U.S. Department of Energy Renews Funding for Argonne-Led Q-NEXT Quantum Research Center The U.S. Department of Energy (DOE) today announced the renewal of funding for Q-NEXT, a National Quantum Information Science Research Center (NQISRC) led by Argonne National Laboratory, in…
Align Technology Opens 2026 Annual Research Award Program to Support Innovation in Orthodontics and Dentistry TEMPE, Ariz., [Date] – Align Technology, Inc. (NASDAQ: ALGN), a global leader in medical devices that designs, manufactures, and sells the Invisalign® System of clear…
Transcat Reports Record Fiscal Q2 2026 Performance Fueled by Double-Digit Growth Transcat delivered another strong quarter, achieving double-digit service revenue growth and continued strength in our rentals channel,” said Lee D. Rudow, President and CEO. “Distribution revenue rose 24% year…
Inducement grants include stock options to purchase 90,750 common shares, awarded to three newly hired non-executive employees Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health…
Northwell Health Honors Recipients of Nine Endowed Chairs and Professorships, Advancing Academic Medicine and Patient Care Northwell Health announced the appointment of nine distinguished clinicians, researchers and educators to endowed chairs and professorships, including several inaugural positions spanning biomedical sciences,…
MaaT Pharma’s Pivotal Phase 3 ARES Trial Results for Xervyteg® (MaaT013) in Steroid- and Ruxolitinib-Refractory GI-aGvHD Selected for Oral Presentation at ASH 2025 MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem…
KCAS Bio Expands Board of Directors with Appointment of Industry Leaders Dr. Paul Kirchgraber and Mr. Kurt Doyle KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, today announced the appointment of Dr. Paul…
Phase III ALLEGORY trial achieved its primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody engineered to enhance B cell depletion. – Gazyva shows potential to become a transformative new standard of care for up to 3.4…